Logo

Sarepta Signs a Two-Year Research and Option Agreement with Codiak for Up to Five Neuromuscular Targets

Share this

Sarepta Signs a Two-Year Research and Option Agreement with Codiak for Up to Five Neuromuscular Targets

Shots:

  • Codiak to receive up to $72.5M upfront- near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future sales of therapies emerges during the collaboration
  • Sarepta gets an exclusive option to license Codiak’s technology to develop and commercialize engineered exosome therapies for up to five neuromuscular targets. Following exercising of an option- Codiak will be responsible for research and preclinical development through IND preparation while Sarepta will lead clinical development and commercial activities
  • The collaboration will leverage Codiak’s exosome engineering capabilities with Sarepta’s expertise in precision genetic medicine to develop next-generation therapeutics targeting the needs of patients with neuromuscular diseases

Click here to read full press release/ article | Ref: Sarepta Therapeutics | Image: STAT


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions